Life Scientist > Biotechnology

Brain cancer drug candidate fast-tracked in clinical trials

10 October, 2022

An experimental drug for advanced solid tumours, including aggressive glioblastoma, has passed the first phase of clinical trials with flying colours.


TGA approves Pfizer vaccine in under-fives

30 September, 2022

The TGA has provisionally approved Pfizer's COVID-19 vaccine for children aged six months and over, and as a booster dose in children five years and over.


Vaxxas to scale up its vaccine skin patch facility

28 September, 2022

Biotech company Vaxxas will receive $8.2m from the Modern Manufacturing Initiative to support the scale-up of its potentially game-changing technology.


New ways to beat chronic pain

09 September, 2022

A new study points to possible treatments for chronic pain with a surprising link to lung cancer.


3D bioprinting and AI help treat diabetes feet, osteoarthritis

08 September, 2022

ROKIT's AI solution recognises the affected area of the patient, using computer vision and deep-learning technology, and then outputs a patch to a 3D printer.


TGA approves Moderna's Omicron-containing booster dose

01 September, 2022

This is the first bivalent COVID-19 vaccine approved for use in Australia, triggering an immune response against the original SARS-CoV-2 virus and the BA.1 Omicron variant.


CHO cells: a staple of recombinant antibody production

25 August, 2022

Recombinant antibody expert Desmond Schofield reveals the astonishing abilities of CHO cells and some of their most interesting characteristics.


New biosynthesis method for producing antibiotics

23 August, 2022

Researchers fluorinated a natural antibiotic via targeted bioengineering — a method through which an entire substance class of medically relevant natural products can be modified.


Epidural nerve block helps treat psoriasis

22 August, 2022

A proof-of-concept pilot study highlights the potential for epidural lidocaine injection as an effective and safe therapeutic strategy for psoriasis treatment.


Moderna to build mRNA manufacturing plant at Monash

16 August, 2022

The state-of-the-art facility, which is expected to produce up to 100 million mRNA respiratory vaccine doses annually, will be located at Monash's campus in Clayton.


CSIRO's 'missing link' lab to develop Aus vaccine pipeline

15 August, 2022

Researchers at the National Vaccine and Therapeutics Lab will turn vaccine and drug candidates into products that can be manufactured in large quantities for clinical trials.


Calling all RNA biotechs — let's collaborate

15 August, 2022

ATA Scientific is helping Australia build a world-class RNA science-based biotech industry.


Nanowires accelerate stem cells' transition into bone

25 July, 2022

Bone-forming stem cells grown on a mesh of these nanowires transform into mature bone much faster than is typical of other culturing conditions.


Diabetes drug to correct metabolic abnormalities

22 July, 2022

PATAS, part of a new class of antidiabetic drugs, can correct the metabolic abnormalities leading to type 2 diabetes and its associated comorbidities.


Spider venom treatment for heart attacks progressing to trials

07 July, 2022

The drug candidate uses a molecule found in the venom of the K’gari funnel-web spider, and can potentially prevent damage caused by heart attacks and stroke.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd